AIM ImmunoTech Inc. issued a press release and corporate presentation titled "The Ampligen Opportunity" to outline the scientific rationale for combining its investigational drug Ampligen with RAS-targeted therapies, specifically Revolution Medicines' daraxonrasib, in the treatment of pancreatic cancer. The filing highlights Phase 3 data for daraxonrasib showing median overall survival of 13.2 months versus 6.7 months with chemotherapy and previously reported exploratory findings from a Named Patient Program where Ampligen-treated patients achieved a median overall survival of 19.7 months. Additionally, the company provided an update on its ongoing Phase 2 DURIPANC study, noting that topline results for clinical benefit rate are expected in Q1 2027 with further analyses anticipated in Q3 2027. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of Ampligen for late-stage pancreatic cancer.
